> Detailanzeige

Mansoor, Wasat; Arkenau, Hendrik-Tobias; ALSINA, MARIA; Shitara, Kohei; Tejani, Mohamedtaki Abdulaziz; Thuss-Patience, Peter C.; Cuffe, Sinead; Dvorkin, Mikhail; Park, David; Ando, Takayuki; Van Den Eynde, Marc; Beretta, Giordano D.; Zaniboni, Alberto; Doi, Toshihiko; Tabernero, Josep; Ilson, David H.; Makris, Lukas; McGuigan, Sandra; Van Cutsem, Eric

Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS
  • Beteiligte: Mansoor, Wasat; Arkenau, Hendrik-Tobias; ALSINA, MARIA; Shitara, Kohei; Tejani, Mohamedtaki Abdulaziz; Thuss-Patience, Peter C.; Cuffe, Sinead; Dvorkin, Mikhail; Park, David; Ando, Takayuki; Van Den Eynde, Marc; Beretta, Giordano D.; Zaniboni, Alberto; Doi, Toshihiko; Tabernero, Josep; Ilson, David H.; Makris, Lukas; McGuigan, Sandra; Van Cutsem, Eric
  • Erschienen: American Society of Clinical Oncology (ASCO), 2019
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.2019.37.15_suppl.4038
  • ISSN: 0732-183X; 1527-7755
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> 4038 </jats:p><jats:p> Background: The incidence of GEJC is increasing in North America and Europe, especially among white men. Many pts present with metastatic disease or relapse locally or systemically after resection of early-stage disease. The global phase 3 study TAGS (NCT02500043) demonstrated the efficacy and safety of FTD/TPI in previously treated pts with metastatic gastric cancer (mGC)/mGEJC. Here we report results in the mGEJC subgroup from TAGS. Methods: Pts with mGC/mGEJC treated with ≥2 prior chemotherapy regimens were randomized (2:1) to receive FTD/TPI (35 mg/m<jats:sup>2</jats:sup> BID on days 1–5 and 8–12 of each 28-day cycle) or placebo, plus best supportive care. A preplanned efficacy and safety analysis was performed in pts with mGEJC. Results: Of 507 randomized pts, 145 (29%) had GEJC as the sole primary disease site (FTD/TPI, 98/337; placebo, 47/170). Of pts with mGEJC, 85% were male and 83% were white (overall population, 73% and 70%). Baseline characteristics were generally balanced for pts with mGEJC across treatment groups, except for fewer pts having prior gastrectomy (40% vs 55%) and more pts having received ≥3 prior regimens (74% vs 66%) in the FTD/TPI group than in the placebo group. FTD/TPI had an efficacy benefit in pts with mGEJC, and the FTD/TPI safety profile was similar in this subgroup and the overall population (table). Conclusions: FTD/TPI showed a manageable safety profile and efficacy benefit in pts with mGEJC in the TAGS trial, despite heavier pretreatment of the FTD/TPI than the placebo group. Clinical trial information: NCT02500043. [Table: see text] </jats:p>
  • Zugangsstatus: Freier Zugang